Iberia Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 1.01 Cr
as on 04-07-2024
- Paid Up Capital ₹ 1.74 M
as on 04-07-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 53.87%
(FY 2023)
- Profit 361.04%
(FY 2023)
- Ebitda 234.68%
(FY 2023)
- Net Worth 125.94%
(FY 2023)
- Total Assets -29.65%
(FY 2023)
About Iberia Pharmaceuticals India
The Corporate was formerly known as Satnam Medical Agencies Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.01 Cr and a paid-up capital of Rs 1.74 M, as per Ministry of Corporate Affairs (MCA) records.
Rishab Jain, Nitin Jain, and Saurav Ojha serve as directors at the Company.
- CIN/LLPIN
U24232DL2013PTC250040
- Company No.
250040
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Mar 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Iberia Pharmaceuticals India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rishab Jain  | Director | 02-May-2021 | Current |
| Nitin Jain | Director | 30-Mar-2013 | Current |
| Saurav Ojha | Director | 30-Sep-2023 | Current |
Financial Performance and Corporate Structure Insights of Iberia Pharmaceuticals India.
Iberia Pharmaceuticals India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 53.87% increase. The company also saw a substantial improvement in profitability, with a 361.04% increase in profit. The company's net worth Soared by an impressive increase of 125.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Iberia Pharmaceuticals India?
In 2023, Iberia Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Iberia Skinbrands India Private LimitedActive 6 years 5 monthsRishab Jain, Nitin Jain and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Iberia Pharmaceuticals India?
Unlock and access historical data on people associated with Iberia Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iberia Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iberia Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
